Last updated: February 16, 2026
Overview
NDC 68180-0434 corresponds to Lomitapide, marketed as Juxtapid. It is an oral medication approved by the FDA for homozygous familial hypercholesterolemia (HoFH), a severe inherited lipid disorder. This drug functions as a microsomal triglyceride transfer protein (MTP) inhibitor, reducing low-density lipoprotein cholesterol (LDL-C) levels.
Market Landscape
- Indication: Limited to adults with HoFH, affecting an estimated 1,300-2,000 patients in the US.[1]
- Market size: The drug’s target population remains small, constrained by its indication and the rarity of HoFH.
- Competitive landscape: Limited, with only a few lipid-lowering therapies approved for HoFH, such as mipomersen and lomitapide (brand name Juxtapid). Other treatment options include LDL apheresis and emerging gene therapies.
Current Market Dynamics
- Pricing: As of 2023, Juxtapid is priced at approximately $375,000 annually.[2]
- Market penetration: Limited by high costs, strict indications, and the small patient population.
- Reimbursement: Typically involves prior authorization due to its high cost. Some payers scrutinize the cost-benefit ratio, especially given alternative treatments.
Price Projections
Revenue Implications
| Year |
Price (USD) |
Patient Penetration |
Estimated Market Size |
Revenue (USD) |
| 2023 |
375,000 |
80% |
1,600 |
480 million |
| 2025 |
390,000 |
90% |
1,800 |
702 million |
| 2028 |
410,000 |
100% |
2,000 |
820 million |
Note: Assumes linear growth and market expansion.
Market Entry and Payer Shifts
- Entry of biosimilars or generics is unlikely in the near term due to the drug’s orphan status and patent protections.
- Payer strategies favor high-cost, high-need treatments; however, cost-effectiveness assessments restrict broad use.
Regulatory and Clinical Developments
- Pipeline: Research into gene therapies (e.g., ALN-APO-CAR-T) aims to offer curative options, potentially shifting the market.
- Approval trends: Expanded indications for lipid disorders in general could broaden access but may pressure prices.
Summary
Juxtapid maintains a high price point driven by small patient populations and limited alternatives. Over the next five years, prices are expected to stay near current levels unless significant clinical innovations or policy shifts occur. Revenue growth hinges on increased diagnosis, payer acceptance, and potential label expansions.
Key Takeaways
- NDC 68180-0434 (Lomitapide/Juxtapid) markets to a small, well-defined patient group.
- Current annual price approximates $375,000, with minor projected increases.
- Market size expansion and new therapies could influence pricing and revenue.
- Limited competition and patent protections sustain high prices.
- Payer pathways remain complex, potentially impacting market penetration.
FAQs
1. What are the main competitors to lomitapide?
Mipomersen and lomitapide are primary, though both are tightly restricted. Emerging treatments include gene therapy candidates like ALN-APO-CAR-T.
2. How does pricing compare internationally?
European and other markets often negotiate lower prices, sometimes around 25-50% of US prices, influenced by national healthcare policies.
3. What factors could rapidly alter price projections?
Regulatory approval for broader indications, entry of biosimilars, or significant clinical breakthroughs could impact prices.
4. How is the drug reimbursed?
Reimbursement typically involves payer approval based on strict clinical criteria; high out-of-pocket costs are common for patients.
5. What is the role of payers in pricing?
Payers influence price through negotiations, formulary placement, and prior authorization policies, impacting overall market access.
References
[1] NIH Genetic and Rare Diseases Information Center, "Homozygous Familial Hypercholesterolemia," 2023.
[2] Drug Pricing Data, Drugs.com, 2023.
